Imovane (Zopiclone)

Zopiclone acts as a positive allosteric modulator at the benzodiazepine binding site of the GABA‑A receptor complex. By enhancing GABA‑mediated chloride influx, it increases neuronal inhibition, producing a calming effect that facilitates sleep onset and maintenance.

The specific dose of Imovane is determined by the prescribing clinician based on the patient’s age, medical history, and severity of insomnia. Typical adult regimens range from low to moderate doses, but the exact amount and frequency must be set by a qualified health professional.

Safety data for Zopiclone in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative sleep‑management options with their healthcare provider.

To request Imovane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imovane belongs to the cyclopyrrolone class, offering a sleep‑inducing effect similar to non‑benzodiazepine hypnotics such as zolpidem, but with a slightly longer half‑life. Compared with traditional benzodiazepines, Zopiclone generally has a lower risk of dependence but still requires short‑term use under medical supervision.

Imovane tablets should be stored at ambient temperature, below 25 °C, in their original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Imovane is taken orally, usually with a glass of water, shortly before bedtime. It should be taken only when the patient can dedicate a full night (7‑8 hours) to sleep, and the tablet should not be split, crushed, or chewed unless specifically instructed by a clinician.

Serious risks include severe allergic reactions, marked depression or suicidal thoughts, respiratory depression—especially when combined with other CNS depressants—and rare skin disorders such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if any of these symptoms occur.

Imovane is contraindicated in individuals with known hypersensitivity to Zopiclone, severe hepatic impairment, untreated sleep‑apnea syndrome, or those who are pregnant or breastfeeding without a clear medical justification. Elderly patients and those with a history of substance misuse should also avoid use unless closely monitored.